ClinicalTrials.gg
Active, not recruitingNCT02257736Updated Nov 4, 2026Results posted

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Phase 3 interventional study of Apalutamide and Abiraterone acetate in Prostatic Neoplasms, sponsored by Aragon Pharmaceuticals, Inc.. Active, not recruiting at 173 sites in 16 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
982
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
6th of 70
982 · median 81
Started
2014
with 2 others
Phase 3
16 of 70
2 open now
Primary completion
2018-03
later than 2 of 35 live
Registered
7th of 70
by date
Lead sponsor
9 of 70
Aragon Pharmaceuticals, Inc.

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 6th largest by enrollment, is one of 3 that started in 2014, is one of 16 in phase 3, reaches primary completion later than 2 of the 35 other live ones, and was the 7th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]).

Read the detailed description

This is a randomized (study drug assigned by chance), double-blind (neither the Investigator nor the participant know the treatment) placebo-controlled and multicenter (when more than 1 hospital or medical school team work on a medical research study) study to determine if participants with chemotherapy-naive mCRPC will benefit from the addition of apalutamide to AAP compared with AAP alone. The study consists of 3 phases: Screening phase; Treatment phase, and Follow-up phase. At the final analysis, the study will be unblinded. After the Independent Data Monitoring Committee (IDMC) review and the sponsor's subsequent decision participants will be offered to receive treatment either in the Open-Label Extension Phase or the Long-Term Extension Phase of study. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Prostatic neoplasms
  • JN56021927
  • ZYTIGA
  • Prednisone
  • Abiraterone acetate
  • Apalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adenocarcinoma of the prostate
  • disease as documented by technetium-99m (99mTc) bone scan or metastatic lesions by computed tomography (CT) or magnetic resonance imaging (MRI) scans (visceral or lymph node disease). If lymph node metastasis is the only evidence of metastasis, it must be greater than or equal to (>=) 2 centimeter (cm) in the longest diameter
  • Castration-resistant prostate cancer demonstrated during continuous androgen deprivation therapy (ADT), defined as 3 rises of PSA, at least 1 week apart with the last androgen deprivation therapy (PSA) >= 2 nanogram per milliliters (ng/mL)
  • Participants who received a first generation anti-androgen (eg, bicalutamide, flutamide, nilutamide) must have at least a 6-week prior to randomization and must show continuing disease (PSA) progression (an increase in PSA) after the washout period
  • Prostate cancer progression documented by prostate-specific antigen (PSA) according to the Prostate Cancer Clinical Trials Working Group (PCWG2) or radiographic progression of soft tissue according to modified , version 1.1 (RECIST) modified based on PCWG2, or radiographic progression of bone according to PCWG2
  • Participants who cross-over from Prednisone alone to open-label apalutamide plus AAP should still be in the double-blind phase of the study, should be receiving AAP alone and should have 0-1-2.

Exclusion criteria

Exclusion Criteria:

  • Small cell or neuroendocrine carcinoma of the prostate
  • Known
  • Prior chemotherapy for prostate cancer, except if administered in the /neoadjuvant setting
  • Previously treated with ketoconazole for prostate cancer for greater than 7 days
  • Therapies that must be discontinued or substituted at least 4 weeks prior to randomization include the following: a) Medications known to lower the seizure threshold, b) Herbal and non-herbal products that may decrease PSA levels (example [eg], saw palmetto, pomegranate) or c) Any agent
  • At Screening need for parenteral or oral opioid analgesics (eg, codeine, dextropropoxyphene)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
982 participants (actual)

Study arms

  • Experimental
    Group 1: AAP and apalutamide

    Participants will receive apalutamide 240 milligram (mg) (4\*60 mg tablets) and abiraterone acetate (AA) 1000 mg (4\*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the Open-Label Extension (OLE) or Long-Term Extension (LTE) phase (AAP + open label apalutamide or AAP alone).

    Drug: Apalutamide · Drug: Abiraterone acetate · Drug: Prednisone

  • Placebo comparator
    Group 2: AAP and Placebo

    Participants will receive matching Placebo of apalutamide and abiraterone acetate (AA) 1000 mg (4\*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the OLE or LTE phase (AAP + open label apalutamide or AAP alone).

    Drug: Abiraterone acetate · Drug: Prednisone · Drug: Placebo

Interventions

  • Participants will receive 240 mg (4\*60 mg tablets) of apalutamide once daily orally.

  • Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.

    Also known as: ZYTIGA

  • Participants will receive 5 mg tablet of prednisone twice daily orally.

  • DrugPlacebo

    Participants will receive matching placebo to apalutamide once daily orally.

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-free Survival (rPFS)

    The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\>=) 2 new lesions compared to baseline was observed in less than (\<) 12 weeks from randomization and was confirmed by a second bone scan taken \>=6 weeks later showing \>=2 additional new lesions (a total of \>=4 new lesions compared to baseline), b) the first bone scan with \>=2 new lesions compared to baseline was observed in \>=12 weeks from randomization and the new lesions were verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Time frame: Up to 3 years and 4 months

Secondary outcomes

  1. Overall Survival (OS)

    The OS was defined as the time from randomization to date of death from any cause.

    Time frame: Up to 5 years and 10 months

  2. Time to Chronic Opioid Use

    Time to chronic opioid use was defined as the time from date of randomization to the first date of opioid use.

    Time frame: Up to 5 years and 10 months

  3. Time to Initiation of Cytotoxic Chemotherapy

    Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy.

    Time frame: Up to 5 years and 10 months

  4. Time to Pain Progression

    Time to pain progression: time from randomization to first date that participant either experienced an increase by 2 points from baseline in Brief Pain Inventory Short Form (BPI-SF) worst pain intensity item (item 3) or Case Report Form (CRF) pain, observed at 2 consecutive evaluations \>=4 wks apart, or initiation of chronic opioids as defined in time to chronic opioid use, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3(worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine." A lower score is better.CRF pain refers to participant's response to global pain assessment "How would you rate your pain over the past 7 days?"with a scale of 0("No pain") to 10("Pain as bad as you can imagine"),that is systematically reported and recorded on the eCRF.

    Time frame: Up to 5 years and 10 months

07

Results

Posted Aug 16, 2021
Limitations and caveats
This study used an electronic handheld device to collect responses for patient-reported outcome (PRO) questionnaires, which might have resulted in a lower-than-expected compliance due to unfamiliarity of the elderly population with the device.

Participant flow

Participant flow — Overall Study
MilestonePlacebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - Prednisolone
Started490492
Completed3945
Not completed451447
Withdrew: Progressive disease365327
Withdrew: Adverse event4556
Withdrew: Withdrawal by subject2138
Withdrew: Death116
Withdrew: Physician decision59
Withdrew: Non-compliance with study drug12
Withdrew: Protocol violation10
Withdrew: Other17
Withdrew: Randomized, not treated12

Outcome measures

PrimaryRadiographic Progression-free Survival (rPFS)

The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\>=) 2 new lesions compared to baseline was observed in less than (\<) 12 weeks from randomization and was confirmed by a second bone scan taken \>=6 weeks later showing \>=2 additional new lesions (a total of \>=4 new lesions compared to baseline), b) the first bone scan with \>=2 new lesions compared to baseline was observed in \>=12 weeks from randomization and the new lesions were verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Time frame:
Up to 3 years and 4 months
Reported as:
Median · months
Radiographic Progression-free Survival (rPFS)
monthsPlacebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - Prednisolone
Radiographic Progression-free Survival (rPFS)16.59 (13.86 to 19.32)23.98 (19.71 to 27.50)
SecondaryOverall Survival (OS)

The OS was defined as the time from randomization to date of death from any cause.

Time frame:
Up to 5 years and 10 months
Reported as:
Median · months
Overall Survival (OS)
monthsPlacebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - Prednisolone
Overall Survival (OS)33.71 (31.24 to 38.28)36.17 (32.76 to 38.77)
SecondaryTime to Chronic Opioid Use

Time to chronic opioid use was defined as the time from date of randomization to the first date of opioid use.

Time frame:
Up to 5 years and 10 months
Reported as:
Median · months
Time to Chronic Opioid Use
monthsPlacebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - Prednisolone
Time to Chronic Opioid Use53.26 (42.02 to NA)46.98 (39.23 to NA)
SecondaryTime to Initiation of Cytotoxic Chemotherapy

Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy.

Time frame:
Up to 5 years and 10 months
Reported as:
Median · months
Time to Initiation of Cytotoxic Chemotherapy
monthsPlacebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - Prednisolone
Time to Initiation of Cytotoxic Chemotherapy34.23 (29.54 to 39.16)36.11 (32.23 to 42.55)
SecondaryTime to Pain Progression

Time to pain progression: time from randomization to first date that participant either experienced an increase by 2 points from baseline in Brief Pain Inventory Short Form (BPI-SF) worst pain intensity item (item 3) or Case Report Form (CRF) pain, observed at 2 consecutive evaluations \>=4 wks apart, or initiation of chronic opioids as defined in time to chronic opioid use, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3(worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine." A lower score is better.CRF pain refers to participant's response to global pain assessment "How would you rate your pain over the past 7 days?"with a scale of 0("No pain") to 10("Pain as bad as you can imagine"),that is systematically reported and recorded on the eCRF.

Time frame:
Up to 5 years and 10 months
Reported as:
Median · months
Time to Pain Progression
monthsPlacebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - Prednisolone
Time to Pain Progression26.51 (22.57 to 29.50)21.82 (17.97 to 25.66)

Adverse events

Collected over Up to 3 years and 4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo+ Abiraterone Acetate - Prednisolone350/489 (71.6%)166/489 (33.9%)459/489 (93.9%)
Apalutamide + Abiraterone Acetate - Prednisolone338/490 (69%)192/490 (39.2%)472/490 (96.3%)
Most frequent serious events
Showing 10 of 259
Most frequent serious events
EventPlacebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - Prednisolone
PneumoniaInfections and infestations10/48918/490
HaematuriaRenal and urinary disorders13/4896/490
Urinary Tract InfectionInfections and infestations7/48912/490
Back PainMusculoskeletal and connective tissue disorders8/4894/490
FallInjury, poisoning and procedural complications1/4898/490
SepsisInfections and infestations7/4895/490
Acute Kidney InjuryRenal and urinary disorders7/4896/490
Atrial FibrillationCardiac disorders6/4893/490
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders6/4891/490
Myocardial InfarctionCardiac disorders1/4896/490
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPlacebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - Prednisolone
FatigueGeneral disorders134/489164/490
Back PainMusculoskeletal and connective tissue disorders133/489154/490
HypertensionVascular disorders122/489144/490
Weight DecreasedInvestigations84/489136/490
ArthralgiaMusculoskeletal and connective tissue disorders121/489127/490
FallInjury, poisoning and procedural complications92/489106/490
ConstipationGastrointestinal disorders94/48996/490
DiarrhoeaGastrointestinal disorders73/48991/490
NauseaGastrointestinal disorders76/48984/490
HypokalaemiaMetabolism and nutrition disorders73/48979/490

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - PrednisoloneTotal
Mean70.7 ± 8.0671.4 ± 8.3471.1 ± 8.21
Sex: Female, Male
Sex: Female, Male(Participants)Placebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - PrednisoloneTotal
Female000
Male490492982
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - PrednisoloneTotal
Hispanic or Latino5450104
Not Hispanic or Latino411422833
Unknown or Not Reported252045
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - PrednisoloneTotal
American Indian or Alaska Native8917
Asian5358111
Black or African American181937
Native Hawaiian or Other Pacific Islander000
White373365738
More than one race000
Unknown or Not Reported202040
Other182139
Region of Enrollment
Region of Enrollment(Participants)Placebo+ Abiraterone Acetate - PrednisoloneApalutamide + Abiraterone Acetate - PrednisoloneTotal
ARGENTINA336
AUSTRALIA314778
BELGIUM161632
BRAZIL211839
CANADA121830
FRANCE181634
GERMANY10919
ITALY333669
JAPAN232750
MEXICO191635
NETHERLANDS141630
RUSSIAN FEDERATION5946105
SOUTH AFRICA9817
SOUTH KOREA282957
SPAIN433679
UNITED KINGDOM232750
UNITED STATES128124252
08

Study locations

173 sites
  • Phoenix, Arizona, United States
  • La Mesa, California, United States
  • Los Angeles, California, United States
  • Modesto, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Santa Barbara, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • Jensen Beach, Florida, United States
  • Lakeland, Florida, United States
  • New Port Richey, Florida, United States
  • Ocala, Florida, United States
  • Atlanta, Georgia, United States
  • Melrose, Illinois, United States
  • Niles, Illinois, United States
  • Marrero, Louisiana, United States
  • New Orleans, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Auburn, Maine, United States
  • Baltimore, Maryland, United States
  • St Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Albany, New York, United States
  • Johnson City, New York, United States
  • New York, New York, United States
  • Poughkeepsie, New York, United States
  • Syracuse, New York, United States
  • The Bronx, New York, United States
  • Columbus, Ohio, United States
  • Tualatin, Oregon, United States
  • Lancaster, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Myrtle Beach, South Carolina, United States
  • Nashville, Tennessee, United States
  • Austin, Texas, United States
  • Houston, Texas, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Auburn, Washington, United States
  • Seattle, Washington, United States
  • Spokane, Washington, United States
  • Wenatchee, Washington, United States
  • Madison, Wisconsin, United States
  • Ciudad Automoma Buenos Aires, Argentina
  • Ciudad de Buenos Aires, Argentina
  • Córdoba, Argentina
  • La Rioja, Argentina
  • Mendoza, Argentina
  • Rosario, Argentina
  • Adelaide, Australia
  • Ashford, Australia
  • Camperdown, Australia
  • Herston, Australia
  • Liverpool, Australia
  • Malvern, Australia
  • Melbourne, Australia
  • Southport, Australia
  • Wahroonga, Australia
  • West Heidelberg, Australia
  • Woolloongabba, Australia
  • Antwerp, Belgium
  • Brussels, Belgium
  • Ghent, Belgium
  • Gosselies, Belgium
  • Leuven, Belgium
  • Liège, Belgium
  • Namur, Belgium
  • Ottignies, Belgium
  • Roeselare, Belgium
  • Sint-Niklaas, Belgium
  • Barretos, Brazil
  • Ijuí, Brazil
  • Natal, Brazil
  • Porto Alegre, Brazil
  • São José do Rio Preto, Brazil
  • São Paulo, Brazil
  • Abbotsford British Columbia, British Columbia, Canada
  • Kelowna, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • Halifax, Nova Scotia, Canada
  • Barrie, Ontario, Canada
  • London, Ontario, Canada
  • Oakville, Ontario, Canada
  • Toronto, Ontario, Canada
  • Weston, Ontario, Canada
  • Montreal, Quebec, Canada
  • Québec, Quebec, Canada
  • Sherbrooke, Quebec, Canada
  • Angers, France
  • Caen, France
  • Dijon, France
  • Le Mans, France
  • Lyon, France
  • Montpellier, France
  • Paris, France
  • Saint-Herblain, France
  • Toulouse, France

Showing the first 100 of 173 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Roy S, Wallis CJD, Morgan SC, Kishan AU, Le ATT, Malone J, Sun Y, Spratt DE, Saad F, Malone S. Implications of metastatic stage at presentation in docetaxel naive metastatic castrate resistant prostate cancer. Prostate. 2023 Jul;83(10):912-921. doi: 10.1002/pros.24512. Epub 2023 Apr 18. PubMed 37071764 ↗
  • Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB Jr, Oudard S, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE; ACIS Investigators. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021 Nov;22(11):1541-1559. doi: 10.1016/S1470-2045(21)00402-2. Epub 2021 Sep 30. PubMed 34600602 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Mar 2018, 39 months.

Results were first posted in Aug 2021, 3 years 4 months after primary completion. A results delay was requested in Mar 2019.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 39 months is close to that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2014
First posted
Oct 6, 2014
StartActual
Nov 26, 2014
Primary completionActual
Mar 19, 2018
CompletionEst.
Dec 31, 2027
Results delay requested
Mar 18, 2019
Results first posted
Aug 16, 2021
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Sep 28, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02257736
Responsible party
Sponsor
First posted
Oct 6, 2014
Start date
Nov 26, 2014
Primary completion
Mar 19, 2018
Completion
Dec 31, 2027 (estimated)
Results posted
Aug 16, 2021
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion